Aytu BioPharma, Inc. (AYTU) Financial Ratios
19 years of historical data (2007–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 2.45
30Y Low2.5·High2.5
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.76
↑+52% vs avg
5yr avg: 0.50
30Y Low0.1·High2.1
ROE
↓
-58.1%
↓+8% vs avg
5yr avg: -63.2%
30Y Low-460%·High-27%
Debt/EBITDA
N/A
—
5yr avg: 3.20
30Y Low3.2·High3.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AYTU Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aytu BioPharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $14M | $16M | $5M | $20M | $84M | $65M | $15M | $3M | $6M | $8M |
| Enterprise Value | $11M | $6M | $13M | $13M | $19M | $65M | $19M | $4M | $-3551407 | $5M | $182610 |
| P/E Ratio → | -1.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.28 | 0.21 | 0.25 | 0.05 | 0.21 | 1.28 | 2.36 | 2.01 | 0.95 | 1.71 | 3.21 |
| P/B Ratio | 0.76 | 0.72 | 0.58 | 0.14 | 0.46 | 0.61 | 0.69 | 2.08 | 0.26 | 1.37 | 0.81 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AYTU EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.09 | 0.19 | 0.12 | 0.20 | 1.00 | 0.70 | 0.50 | -0.97 | 1.47 | 0.07 |
| EV / EBITDA | — | — | 2.45 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AYTU Profitability
Margins and return-on-capital ratios measuring operating efficiency
Aytu BioPharma, Inc. earns an operating margin of -11.8%. Operating margins have expanded from -15.9% to -11.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -58.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0% | 69.0% | 75.3% | 62.0% | 52.0% | 44.5% | 70.0% | 69.9% | 44.0% | 56.0% | 62.6% |
| Operating Margin | -11.8% | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -230.1% | -538.3% | -624.7% | -847.0% |
| Net Profit Margin | -20.4% | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -644.3% | -278.4% | -698.7% | -1099.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -47.2% | -40.8% | -119.6% | -50.1% | -26.7% | -459.9% | -116.9% | -319.6% | -219.3% |
| ROA | -11.2% | -11.2% | -12.3% | -12.4% | -53.9% | -27.8% | -14.5% | -169.1% | -56.5% | -114.4% | -132.4% |
| ROIC | -33.5% | -33.5% | -3.4% | -28.5% | -101.7% | -52.6% | -70.5% | -1029.1% | -307.5% | -577.4% | -316.3% |
| ROCE | -13.3% | -13.3% | -2.5% | -24.0% | -95.8% | -41.9% | -27.5% | -71.7% | -135.6% | -157.1% | -140.1% |
AYTU Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $31M exceeds total debt of $23M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.21 | 1.21 | 0.59 | 0.77 | 0.41 | 0.23 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | 3.20 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.42 | -0.13 | 0.19 | -0.03 | -0.14 | -0.48 | -1.56 | -0.52 | -0.20 | -0.80 |
| Net Debt / EBITDA | — | — | -0.70 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.71 | -2.71 | -1.11 | -2.44 | -0.26 | — | — | — | -23.81 | -7.88 | -4.13 |
Net cash position: cash ($31M) exceeds total debt ($23M)
AYTU Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.26x means Aytu BioPharma, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.06x to 1.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 | 2.62 | 2.87 | 2.79 | 0.84 | 1.00 |
| Quick Ratio | 1.07 | 1.07 | 0.80 | 0.88 | 0.76 | 0.81 | 2.27 | 2.60 | 2.40 | 0.48 | 0.95 |
| Cash Ratio | 0.49 | 0.49 | 0.32 | 0.33 | 0.30 | 0.45 | 1.67 | 2.06 | 2.07 | 0.22 | 0.90 |
| Asset Turnover | — | 0.53 | 0.55 | 0.78 | 0.70 | 0.25 | 0.18 | 0.21 | 0.17 | 0.21 | 0.11 |
| Inventory Turnover | 1.80 | 1.80 | 1.33 | 3.40 | 4.28 | 2.23 | 0.83 | 1.53 | 1.53 | 1.08 | 1.82 |
| Days Sales Outstanding | — | 171.31 | 131.74 | 98.34 | 81.98 | 156.70 | 74.41 | 86.80 | 57.72 | 59.83 | 23.14 |
AYTU Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aytu BioPharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $6M | $3M | $1M | $840000 | $230000 | $38972 | $3328 | $117 | $22 |
Peer Comparison
Compare AYTU with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AYTUYou | $19M | -1.1 | — | — | 69.0% | -11.8% | -58.1% | -33.5% | — |
 SUPN | $3B | -65.3 | 45.1 | 55.6 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 TPVG | $203M | 4.1 | 8.6 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 ASRT | $152M | -5.0 | 14.1 | — | 44.9% | -14.5% | -28.3% | -11.1% | 3.1 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 COLL | $1B | 19.4 | 4.3 | 3.3 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 JAZZ | $14B | -38.5 | 23.7 | 10.9 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 TEVA | $37B | 26.2 | 16.0 | 31.9 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 PAHC | $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 19 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AYTU — Frequently Asked Questions
Quick answers to the most common questions about buying AYTU stock.
What is Aytu BioPharma, Inc.'s P/E ratio?
Aytu BioPharma, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Aytu BioPharma, Inc.'s ROE?
Aytu BioPharma, Inc.'s return on equity (ROE) is -58.1%. The historical average is -161.4%.
Is AYTU stock overvalued?
Based on historical data, Aytu BioPharma, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Aytu BioPharma, Inc.'s profit margins?
Aytu BioPharma, Inc. has 69.0% gross margin and -11.8% operating margin.